Corcept stock tanks as FDA setback hits relacorilant for Cushing’s syndrome. Truist analysts believe CORT shares pullback may be overdone.
Why Corcept Therapeutics stock crashed today and what comes next?
view original post
Corcept stock tanks as FDA setback hits relacorilant for Cushing’s syndrome. Truist analysts believe CORT shares pullback may be overdone.